We are live on ! Find out more
WCBA

Weaver C. Barksdale & Associates Portfolio holdings

AUM $105M
1-Year Est. Return 13.81%
This Fund
S&P 500
This Quarter Est. Return
-10.12%
1 Year Est. Return
+13.81%
3 Year Est. Return
+40.08%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$107M
AUM Growth
-$4.89M
Cap. Flow
+$7.59M
Cap. Flow %
7.07%
Top 10 Hldgs %
20.41%
Holding
66
New
5
Increased
54
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
QCOM icon
Qualcomm
QCOM
+$2.15M
2
UL icon
Unilever
UL
+$2.08M
3
CMCSA icon
Comcast
CMCSA
+$1.97M
4
MRK icon
Merck
MRK
+$375K
5
CAH icon
Cardinal Health
CAH
+$238K

Top Sells

Rank Stock Value
1
HUBB icon
Hubbell
HUBB
+$1.89M
2
INTC icon
Intel
INTC
+$1.37M
3
PARA
Paramount Global Class B
PARA
+$864K
4
ABBV icon
AbbVie
ABBV
+$528K
5
T icon
AT&T
T
+$239K

Sector Composition

Rank Sector Weight
1 Financials 20.41%
2 Healthcare 17.76%
3 Industrials 11.32%
4 Technology 10.28%
5 Energy 9.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
1
Amgen
AMGN
$203B
$2.51M 2.33%
10,310
+742
+8% +$182K
OGE icon
2
OGE Energy
OGE
$10.3B
$2.31M 2.15%
59,941
+3,562
+6% +$142K
ABBV icon
3
AbbVie
ABBV
$458B
$2.23M 2.08%
14,552
-3,457
-19% -$528K
NXST icon
4
Nexstar Media Group
NXST
$5.6B
$2.22M 2.07%
13,638
+808
+6% +$136K
GPC icon
5
Genuine Parts
GPC
$17.1B
$2.18M 2.03%
16,381
+982
+6% +$131K
AFL icon
6
Aflac
AFL
$63.9B
$2.18M 2.03%
39,359
+2,337
+6% +$138K
UL icon
7
Unilever
UL
$131B
$2.11M 1.96%
+40,896
New +$2.08M
MET icon
8
MetLife
MET
$61B
$2.1M 1.95%
33,414
+1,981
+6% +$131K
CVX icon
9
Chevron
CVX
$388B
$2.08M 1.93%
14,353
+881
+7% +$146K
QCOM icon
10
Qualcomm
QCOM
$176B
$2.02M 1.88%
+15,796
New +$2.15M
PKG icon
11
Packaging Corp of America
PKG
$22.7B
$1.99M 1.85%
14,436
+856
+6% +$132K
PFE icon
12
Pfizer
PFE
$140B
$1.98M 1.85%
37,817
+382
+1% +$19.5K
AAPL icon
13
Apple
AAPL
$4.89T
$1.97M 1.84%
14,438
+841
+6% +$127K
TD icon
14
Toronto Dominion Bank
TD
$198B
$1.97M 1.83%
30,054
+1,783
+6% +$129K
TRP icon
15
TC Energy
TRP
$73.5B
$1.95M 1.82%
37,676
+2,248
+6% +$125K
DGX icon
16
Quest Diagnostics
DGX
$25.1B
$1.95M 1.81%
14,652
+879
+6% +$120K
CVS icon
17
CVS Health
CVS
$137B
$1.95M 1.81%
21,012
+1,391
+7% +$136K
TSN icon
18
Tyson Foods
TSN
$20.2B
$1.94M 1.81%
22,534
+1,345
+6% +$121K
LMT icon
19
Lockheed Martin
LMT
$134B
$1.93M 1.8%
4,488
+259
+6% +$114K
EOG icon
20
EOG Resources
EOG
$78B
$1.93M 1.79%
17,451
-584
-3% -$72.5K
VZ icon
21
Verizon
VZ
$194B
$1.92M 1.79%
37,845
+2,264
+6% +$115K
MRK icon
22
Merck
MRK
$324B
$1.92M 1.78%
21,021
+4,233
+25% +$375K
GD icon
23
General Dynamics
GD
$105B
$1.9M 1.77%
8,597
+511
+6% +$118K
PRU icon
24
Prudential Financial
PRU
$41.7B
$1.9M 1.77%
19,831
+1,185
+6% +$125K
AVGO icon
25
Broadcom
AVGO
$1.82T
$1.85M 1.72%
38,130
+2,100
+6% +$118K
1
2 3

Similar funds

EW
Expressive Wealth Chicago, Illinois $105M AUM
AFG
Artesa Financial Group Conroe, Texas $105M AUM
ANBOT
American National Bank of Texas Richardson, Texas $105M AUM
P
Palladiem Bryn Mawr, Pennsylvania $105M AUM
SPW
Signet Private Wealth Chicago, Illinois $105M AUM
SHF
Safe Harbor Fiduciary Pensacola, Florida $105M AUM
NS
Northland Securities Minneapolis, Minnesota $105M AUM
ACA
Alpha Capital Advisors Bangor, Maine $105M AUM

Weaver C. Barksdale & Associates's Q2 2022 Portfolio in Review

As of Q2 2022, Weaver C. Barksdale & Associates held 66 positions worth $107M, down 4.4% from $112M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Weaver C. Barksdale & Associates deployed $7.59M of net new capital in Q2 2022, opening 5 new positions and adding to 54 existing holdings. Its largest new stake was Qualcomm: 15,796 shares worth $2.02M.

By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 22% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was AbbVie, an estimated $528K trimmed.

  • Weaver C. Barksdale & Associates's largest Q2 2022 buy was Qualcomm: 15,796 shares worth $2.02M.
  • Weaver C. Barksdale & Associates added most to Merck in Q2 2022, an estimated $375K increase.
  • Weaver C. Barksdale & Associates's biggest Q2 2022 reduction was AbbVie, cutting an estimated $528K.
  • Weaver C. Barksdale & Associates fully exited Hubbell in Q2 2022, selling an estimated $1.89M.
  • Weaver C. Barksdale & Associates's ten largest holdings make up 20% of its $107M portfolio in Q2 2022.
  • Weaver C. Barksdale & Associates opened 5 new positions and closed 3 in Q2 2022.
  • Weaver C. Barksdale & Associates's portfolio value fell 4.4% quarter-over-quarter to $107M.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2022, filed 11 Aug 2022.